Announcements Trials
Browse Landscape

Phase

Phase 2 3Phase 1 1

Status

Recruiting 1Not yet recruiting 1Active not recruiting 1

Sponsor Class

OTHER 3

Study Type

Interventional 3

Sponsor

Cancer Type

Thoracic 3Head & Neck 1Genitourinary 1Dermatologic 1

Conditions

Carcinoma, Non-Small-Cell Lung 3Myelodysplastic Syndromes 2Melanoma 2Leukemia, Myeloid, Acute 2Hematologic Neoplasms 2Carcinoma, Hepatocellular 2Stomach Neoplasms 1Squamous Cell Carcinoma of Head and Neck 1Prostatic Neoplasms 1Non Small Cell Lung Cancer Metastatic 1Neoplasms, Plasma Cell 1Neoplasms 1Neoplasm Metastasis 1Lymphoma, Non-Hodgkin 1Lymphoma, Large B-Cell, Diffuse 1Lymphoma 1Lung Neoplasms 1Leukemia, Lymphocytic, Chronic, B-Cell 1Leukemia 1Hodgkin Disease 1Graft vs Host Disease 1Colorectal Neoplasms 1Colonic Neoplasms 1Carcinoma, Renal Cell 1Cachexia 1Acute Graft Versus Host Disease 1

Interventions

Carboplatin 361Pemetrexed 276Cisplatin 230Paclitaxel 213Docetaxel 205Gemcitabine 160Erlotinib Hydrochloride 150Bevacizumab 132pembrolizumab 129Radiotherapy 114Nivolumab 88durvalumab 84Drug Therapy 84osimertinib 82atezolizumab 58Vinorelbine 53Gefitinib 53Radiosurgery 50Cetuximab 39Taxes 37130-nm albumin-bound paclitaxel 36Ipilimumab 34anlotinib 33Surgical Procedures, Operative 33Magnetic Resonance Spectroscopy 33Etoposide 30Albumin-Bound Paclitaxel 29tislelizumab 27icotinib 27aflutinib 26

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Phase 2 × Carcinoma, Non-Small-Cell Lung × Fecal Microbiota Transplantation × Clear all
NCT07432984 2026-02-25

FMT-LUNG

Samsung Medical Center

Phase 2 Not yet recruiting
15 enrolled
Thoracic

Carcinoma, Non-Small-Cell Lung

NCT05286294 2025-07-03

MITRIC

Oslo University Hospital

Phase 2 Active not recruiting
20 enrolled
DermatologicGenitourinaryHead & NeckThoracic

Squamous Cell Carcinoma of Head and Neck, Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Melanoma

NCT06403111 2024-12-20

FMT+Immunotherapy+Chemotherapy As First-line Treatment for Driver-gene Negative Advanced NSCLC

Changzhou No.2 People's Hospital

Phase 2 Recruiting
62 enrolled
Thoracic

Carcinoma, Non-Small-Cell Lung

Data powered by HemOnc (CC BY 4.0) Colophon âš¡